Rayman, Margaret, Blundell-Pound, Gabrielle, Pastor-Barriuso, R., Guallar, Eliseo, Steinbrenner, Holger and Stranges, Saverio. (2012) A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. PLoS One, Vol.7 (No.9). e45269. ISSN 1932-6203

Preview

Text WRAP_Stranges_journal.pone.0045269.pdf - Published Version Download (534Kb) | Preview

Abstract

Background: Evidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabetes in a population of relatively low selenium status as part of the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study. Plasma adiponectin concentration, a recognised independent predictor of type-2 diabetes risk and known to be correlated with circulating selenoprotein P, was the biomarker chosen. Methods: In a randomized, double-blind, placebo-controlled trial, five hundred and one elderly volunteers were randomly assigned to a six-month intervention with 100, 200 or 300 μg selenium/d as high-selenium or placebo yeast. Adiponectin concentration was measured by ELISA at baseline and after six months of treatment in 473 participants with one or both plasma samples available. Results: Mean (SD) plasma selenium concentration was 88.5 ng/g (19.1) at baseline and increased significantly in the selenium-treatment groups. In baseline cross-sectional analyses, the fully adjusted geometric mean of plasma adiponectin was 14% lower (95% CI, 0-27%) in the highest than in the lowest quartile of plasma selenium (P for linear trend = 0.04). In analyses across randomized groups, however, selenium supplementation had no effect on adiponectin levels after six months of treatment (P = 0.96). Conclusions: These findings are reassuring as they did not show a diabetogenic effect of a six-month supplementation with selenium in this sample of elderly individuals of relatively low selenium status.

Item Type:	Journal Article
Subjects:	Q Science > QP Physiology R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Selenium -- Physiological effect, Non-insulin-dependent diabetes -- Susceptibility
Journal or Publication Title:	PLoS One
Publisher:	Public Library of Science
ISSN:	1932-6203
Date:	2012
Volume:	Vol.7
Number:	No.9
Page Range:	e45269
Identification Number:	10.1371/journal.pone.0045269
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	Cancer Research UK (CRUK), University of Surrey, Pharma Nord (Denmark), Deutsche Forschungsgemeinschaft (DFG)
Grant number:	STE 1782/2-2 (DFG)
References:	1. McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, et al. (2004) Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci U S A 101: 8852–7. 2. Wang XD, Vatamaniuk MZ, Wang SK, Roneker CA, Simmons RA, et al. (2008) Molecular mechanisms for hyperinsulinaemia induced by overproduction of selenium-dependent glutathione peroxidase-1 in mice. Diabetologia 51: 1515– 24. 3. Speckmann B, Sies H, Steinbrenner H (2009) Attenuation of hepatic expression and secretion of selenoprotein P by metformin. Biochem Biophys Res Commun 387: 158–63. 4. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, et al. (2010) A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 12: 483–95. 5. Misu H, Ishikura K, Kurita S, Takeshita Y, Ota T, et al. (2012) Inverse Correlation between Serum Levels of Selenoprotein P and Adiponectin in Patients with Type 2 Diabetes. PLoS One 7(4):e34952. 6. Yang SJ, Hwang SY, Choi HY, Yoo HJ, Seo JA, et al. (2011) Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrin Metab 96: E1325–9. 7. Steinbrenner H, Speckmann B, Pinto A, Sies H (2011) High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J Clin Biochem Nutr 48: 40–5. 8. Bleys J, Navas-Acien A, Guallar E (2007) Serum selenium and diabetes in U.S. adults. Diabetes Care 30: 829–834. 9. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E (2009) Serum selenium concentrations and diabetes in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2003–2004. Environ Health Perspect 117: 1409–1413. 10. Stranges S, Galletti F, Farinaro E, D’Elia L, Russo O, et al. (2011) Associations of selenium status with cardiometabolic risk factors: an 8-year follow-up analysis of the Olivetti Heart study. Atherosclerosis 217: 274–8. 11. Czernichow S, Couthouis A, Bertrais S, Vergnaud AC, Dauchet L, et al. (2006) Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. Am J Clin Nutr 84: 395–399. 12. Akbaraly TN, Arnaud J, Rayman MP, Hininger-Favier I, Roussel AM, et al. (2010) Plasma selenium and risk of dysglycemia in an elderly French population: results from the prospective Epidemiology of Vascular Ageing Study. Nutr Metab (Lond) 7: 21–7. 13. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, et al. (2007) Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med 147: 217–223. 14. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39–51. 15. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, et al. (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306: 1549–56. 16. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595–9. 17. Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302: 179–88. 18. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, et al. (2010) Associations between leptin and the leptin/adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984–2002. Diabet Med 27: 1004–11. 19. Zhu N, Pankow JS, Ballantyne CM, Couper D, Hoogeveen RC, et al. (2010) High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab 95: 5097–104. 20. Montonen J, Drogan D, Joost HG, Boeing H, Fritsche A, et al. (2011) Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes. Eur J Epidemiol 26: 29–38. 21. Qatanani M, Lazar MA (2007) Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21: 1443–55. 22. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439–51. 23. Schoenmakers E, Agostini M, Mitchell C, Schoenmakers N, Papp L, et al. (2010) Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest 120: 4220–35. 24. Vunta H, Davis F, Palempalli UD, Bhat D, Arner RJ, et al. (2007) The antiinflammatory effects of selenium are mediated through 15-deoxy-Delta12,14- prostaglandin J2 in macrophages. J Biol Chem 282: 17964–73. 25. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094–9. 26. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, et al. (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143: 998–1007. 27. Zhang Y, Chen X (2011) Reducing selenoprotein P expression suppresses adipocyte differentiation as a result of increased preadipocyte inflammation. Am J Physiol Endocrinol Metab 300: E77–85. 28. Salas-Salvado´ J, Granada M, Bullo´ M, Corominas A, Casas P, et al. (2007) Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome. Metabolism 56: 1486–92. 29. Rayman MP, Stranges S, Griffin BA, Pastor-Barriuso R, Guallar E (2011) Effect of supplementation with high-selenium yeast on plasma lipids: a randomised trial. Ann Intern Med 54: 656–665. 30. Rayman MP (2011) Selenium and adverse conditions of human pregnancy. In: Hatfield DL, Berry MJ and Gladyshev VN, editors. Selenium: Its molecular biology and role in human health. 3rd ed. New York, NY: Springer Science+Business Media, LLC. Chapter 42, 531–546. 31. Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, et al. (2003) Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 88: 2838–43. 32. Shand B, Elder P, Scott R, Frampton C, Willis J (2006)) Biovariability of plasma adiponectin. Clin Chem Lab Med 44: 1264–8. 33. Rayman MP, Thompson A, Warren-Perry M, Galassini R, Catterick J, et al. (2006) Impact of selenium on mood and quality of life: a randomised controlled trial. Biol Psychiatry 59: 147–54. 34. Rayman MP, Thompson AJ, Bekaert B, Catterick J, Galassini R, et al. (2008) Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. Am J Clin Nutr 87: 370– 8. 35. CRC Handbook of Chemistry and Physics (1993–1994) 74th edition, David R. Lide, editor. Boca Raton, USA: CRC Press. 36. Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440: 944–48. 37. Labunskyy VM, Lee BC, Handy DE, Loscalzo J, Hatfield DL, et al. (2011) Both maximal expression of selenoproteins and selenoprotein deficiency can promote development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal 14: 2327–36. 38. Pinto A, Juniper DT, Sanil M, Morgan L, Clark L, et al. (2012) Supranutritional selenium induces alterations in molecular targets related to energy metabolism in skeletal muscle and visceral adipose tissue of pigs. J Inorg Biochem 114C: 47–54. 39. Kantartzis K, Fritsche A, Tschritter O, Thamer C, Haap M, et al. (2005) The association between plasma adiponectin and insulin sensitivity in humans depends on obesity. Obes Res 13: 1683–91. 40. Stenholm S, Koster A, Alley DE, Visser M, Maggio M, et al. (2010) Adipocytokines and the metabolic syndrome among older persons with and without obesity: the InCHIANTI study. Clin Endocrinol (Oxf) 73: 55–65. 41. You T, Nicklas BJ, Ding J, Penninx BW, Goodpaster BH, et al. (2008) The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. J Gerontol A Biol Sci Med Sci 63: 414–9. 42. Mueller AS, Bosse AC, Most E, Klomann SD, Schneider S, et al. (2009)) Regulation of the insulin antagonistic protein tyrosine phosphatase 1B by dietary Se studied in growing rats. J Nutr Biochem 20: 235–247. 43. Mueller AS, Mueller K, Wolf NM, Pallauf J (2009) Selenium and diabetes: an enigma? Free Radic Res 43: 1029–1059. 44. Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, et al. (2010) Establishing optimal selenium status: results of a randomized, double-blind, placebocontrolled trial. Am J Clin Nutr 91: 923–31. 45. Stranges S, Navas-Acien A, Rayman MP, Guallar E (2010) Selenium status and cardio-metabolic health: state of the evidence. Nut Metab Cardiovasc Dis 20: 754–60. 46. Hu Y, McIntosh GH, Le Leu RK, Upton JM, Woodman RJ, et al. (2011) The influence of selenium-enriched milk proteins and selenium yeast on plasma selenium levels and rectal selenoprotein gene expression in human subjects. Br J Nutr 106: 572–82. 47. Alizadeh M, Safaeiyan A, Ostadrahimi A, Estakhri R, Daneghian S, et al. (2012) Effect of L-arginine and selenium added to a hypocaloric diet enriched with legumes on cardiovascular disease risk factors in women with central obesity: a randomized, double-blind, placebo-controlled trial. Ann Nutr Metab 60: 157– 68. 48. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, et al. (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51: 2968–74.
URI:	http://wrap.warwick.ac.uk/id/eprint/50176

Request changes to a record

Actions (login required)

View Item